Business
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in ESMO Open, characterizing the management of adverse events on treatment adherence and efficacy of VYLOY (zolbetuximab) plus chemotherapy and evaluating stra
About this update from Astellas Pharma Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY plus chemotherapy when data from patients who discontinued early due to common adverse events were censored ","length":308,"tagName":"p"}]},{"val":[{"type":"text","content":"Effective management of adverse events remains an important component of supportive care for patients receiving treatment for advanced gastric or GEJ cancer","length":161,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":469,"olType":false},{"type":"text","content":"NORTHBROOK, Ill., Jan. 8, 2026 /PRNewswire/ -- Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in ESMO Open, characterizing the management of adverse events on treatment adherence and efficacy of VYLOY (zolbetuximab) plus chemotherapy and evaluating strategies for managing these side effects.","length":601,"tagName":"p"},{"type":"image","alt":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","displaySize":"","headline":null,"caption":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":110,"url":"https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gt2H1Ajgjzgw_owZJZe3uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b","width":400,"height":110}},"href":"https://mma.prnewswire.com/media/458529/Astellas_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The exploratory analyses, which included 1,072 patients, reported higher mPFS and mOS estimates ...